Akt inhibitor MK-2206 in combination with Bendamustine and Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results from the N1087 Alliance Study

Akt is a downstream target of B cell receptor signaling and is a central regulator of CLL cell survival. We aim to investigate the safety and efficacy of the Akt inhibitor MK-2206 in combination with bendamustine and rituximab (BR) in relapsed and/or refractory CLL in a phase I/II study. A standard...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Hematol
Main Authors: Larsen, Jeremy T., Shanafelt, Tait D., Leis, Jose F., LaPlant, Betsy, Call, Tim, Pettinger, Adam, Hanson, Curtis, Erlichman, Charles, Habermann, Thomas Matthew, Reeder, Craig, Nikcevich, Daniel, Bowen, Deborah, Conte, Michael, Boysen, Justin, Secreto, Charla, Lesnick, Connie, Tschumper, Renee, Jelinek, Diane, Kay, Neil E., Ding, Wei
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507724/
https://ncbi.nlm.nih.gov/pubmed/28402581
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24762
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados